{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:57Z","timestamp":1793414157659,"version":"4.5.0"},"reference-count":74,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Autologous T-cell\u2013based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional T-cell phenotype observed in patients. Despite various proposed mechanisms of T-cell dysfunction in CLL, the specific CLL-derived factors responsible remain unidentified. This study aimed to investigate the mechanisms through which CLL cells suppress CAR T-cell activation and function. We found that CLL-derived T cells get activated, albeit in a delayed fashion, and specifically that restimulation of CAR T cells in the presence of CLL cells causes impaired cytokine production and reduced proliferation. Notably, coculture of T cells with CD40-activated CLL cells did not lead to T-cell dysfunction, and this required direct cell contact between the CD40-stimulated CLL cells and T cells. Inhibition of kinases involved in the CD40 signaling cascade revealed that the Spare Respiratory Capacity (SRC) kinase inhibitor dasatinib prevented rescue of T-cell function independent of CD40-mediated increased levels of costimulatory and adhesion ligands on CLL cells. Transcriptome profiling of CD40-stimulated CLL cells with or without dasatinib identified widespread differential gene expression. Selecting for surface receptor genes revealed CD40-mediated downregulation of the Sialic acid-binding Ig-like lectin 10 (Siglec-10) ligands CD24 and CD52, which was prevented by dasatinib, suggesting a role for these ligands in functional T-cell suppression in CLL. Indeed, blocking CD24 and\/or CD52 markedly reduced CAR T-cell dysfunction upon coculture with resting CLL cells. These results demonstrated that T cells derived from CLL patients can be reinvigorated by manipulating CLL\u2013T-cell interactions. Targeting CD24- and CD52-mediated CLL\u2013T-cell interaction could be a promising therapeutic strategy to enhance T-cell function in CLL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011934","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T21:05:15Z","timestamp":1721768715000},"page":"4633-4646","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-6754","authenticated-orcid":false,"given":"Jaco A. C.","family":"van Bruggen","sequence":"first","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-315X","authenticated-orcid":false,"given":"Fleur S.","family":"Peters","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Mes","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-4521","authenticated-orcid":false,"given":"Joanne M.","family":"Rietveld","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-5009","authenticated-orcid":false,"given":"Elisa","family":"Cerretani","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspard","family":"Cretenet","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"van Kampen","sequence":"additional","affiliation":[{"name":"3Zuyderland Medical Center, Sittard-Geleen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8948-2549","authenticated-orcid":false,"given":"Aldo","family":"Jongejan","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Data Science, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-3659","authenticated-orcid":false,"given":"Perry D.","family":"Moerland","sequence":"additional","affiliation":[{"name":"4Department of Epidemiology and Data Science, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-537X","authenticated-orcid":false,"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[{"name":"5Cleveland Clinic, Lerner Research Institute, Center for Immunotherapy & Precision Immuno-Oncology, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerritje J. W.","family":"van der Windt","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-6640","authenticated-orcid":false,"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"12","key":"2024091013003393700_bib1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrclinonc.2015.206","article-title":"Can FCR be curative in CLL?","volume":"12","author":"Killock","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"2024091013003393700_bib2","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"7897","key":"2024091013003393700_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"5","key":"2024091013003393700_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"13","key":"2024091013003393700_bib5","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2024091013003393700_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"issue":"303","key":"2024091013003393700_bib7","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7","key":"2024091013003393700_bib8","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2024091013003393700_bib9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2024091013003393700_bib10","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.4049\/jimmunol.1502464","article-title":"Suppression of Glut1 and glucose metabolism by decreased Akt\/mTORC1 signaling drives T cell impairment in B cell leukemia","volume":"197","author":"Siska","year":"2016","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2024091013003393700_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy","volume":"134","author":"van Bruggen","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2024091013003393700_bib12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8\u00a0T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"2024091013003393700_bib13","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers12123837","article-title":"Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-Hodgkin lymphoma","volume":"12","author":"van Bruggen","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"2024091013003393700_bib14","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2024091013003393700_bib15","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4\u00a0T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024091013003393700_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1158\/1078-0432.CCR-20-1632","article-title":"Exploiting B-cell receptor stereotypy to design tailored immunotherapy in chronic lymphocytic leukemia","volume":"27","author":"Rovida","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024091013003393700_bib17","doi-asserted-by":"crossref","first-page":"1097942","DOI":"10.3389\/fonc.2023.1097942","article-title":"T\u00a0cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations","volume":"13","author":"Vlachonikola","year":"2023","journal-title":"Front Oncol"},{"key":"2024091013003393700_bib18","doi-asserted-by":"crossref","first-page":"612244","DOI":"10.3389\/fimmu.2020.612244","article-title":"T\u00a0cells in chronic lymphocytic leukemia: a two-edged sword","volume":"11","author":"Vlachonikola","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2024091013003393700_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2021-152422","article-title":"The clonotypic BCR IG of CLL patients contain predicted T-cell class I epitopes with shared structural properties","volume":"138","author":"Vardi","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024091013003393700_bib20","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002","article-title":"CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells","volume":"93","author":"Buhmann","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2024091013003393700_bib21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/2767-9764.CRC-22-0200","article-title":"Enhanced co-stimulatory signaling improves CAR T cell effector responses in CLL","volume":"2","author":"Collins","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"4","key":"2024091013003393700_bib22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2141.2004.05225.x","article-title":"CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack","volume":"127","author":"Kater","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2024091013003393700_bib23","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","article-title":"Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia","volume":"102","author":"Mackus","year":"2003","journal-title":"Blood"},{"key":"2024091013003393700_bib24","unstructured":"R: A Language and Environment for Statistical Computing. Team RC. 2021. Accessed 25 March 2024. https:\/\/www.R-project.org\/."},{"issue":"5","key":"2024091013003393700_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2024091013003393700_bib26","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2011.111","article-title":"Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL","volume":"25","author":"Hofbauer","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"2024091013003393700_bib27","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1097\/HS9.0000000000000337","article-title":"Functional differences between EBV- and CMV-specific CD8+ T cells demonstrate heterogeneity of T cell dysfunction in CLL","volume":"4","author":"Hofland","year":"2020","journal-title":"HemaSphere"},{"issue":"3","key":"2024091013003393700_bib28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024091013003393700_bib29","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3390\/cancers13123084","article-title":"Co-stimulatory versus cell death aspects of agonistic CD40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia","volume":"13","author":"Delgado","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"2024091013003393700_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdh213","article-title":"CD40 activation: potential for specific immunotherapy in B-CLL","volume":"15","author":"von Bergwelt-Baildon","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"2024091013003393700_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/sj.leu.2400598","article-title":"CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules","volume":"11","author":"Van den Hove","year":"1997","journal-title":"Leukemia"},{"issue":"12","key":"2024091013003393700_bib32","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/leu.2017.129","article-title":"Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition","volume":"31","author":"Slinger","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"2024091013003393700_bib33","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches","volume":"112","author":"Hallaert","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2024091013003393700_bib34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"issue":"8","key":"2024091013003393700_bib35","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024091013003393700_bib36","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2024091013003393700_bib37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2141.2008.07418.x","article-title":"Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in\u00a0vitro","volume":"143","author":"Amrein","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2024091013003393700_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-11-1440","article-title":"Tipping the Noxa\/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia","volume":"18","author":"Tromp","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2024091013003393700_bib39","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2024091013003393700_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.177.4.925","article-title":"Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal","volume":"177","author":"Ranheim","year":"1993","journal-title":"J\u00a0Exp Med"},{"issue":"23","key":"2024091013003393700_bib41","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1073\/pnas.79.23.7489","article-title":"Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3","volume":"79","author":"Sanchez-Madrid","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2024091013003393700_bib42","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1073\/pnas.0808144106","article-title":"In\u00a0vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses","volume":"106","author":"Evans","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024091013003393700_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V86.3.1115.1115","article-title":"Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia","volume":"86","author":"Decker","year":"1995","journal-title":"Blood"},{"issue":"8","key":"2024091013003393700_bib44","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V91.8.2689.2689_2689_2697","article-title":"Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity","volume":"91","author":"Schattner","year":"1998","journal-title":"Blood"},{"issue":"13","key":"2024091013003393700_bib45","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2003-12-4291","article-title":"Tracking CD40 signaling during germinal center development","volume":"104","author":"Basso","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2024091013003393700_bib46","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2024091013003393700_bib47","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2004-02-0494","article-title":"Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells","volume":"104","author":"Gricks","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2024091013003393700_bib48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-020-00292-x","article-title":"Deciphering cell-cell interactions and communication from gene expression","volume":"22","author":"Armingol","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2024091013003393700_bib49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"2024091013003393700_bib50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ni.2610","article-title":"T\u00a0cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat Immunol"},{"issue":"5922","key":"2024091013003393700_bib51","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1126\/science.1168988","article-title":"CD24 and Siglec-10 selectively repress tissue damage-induced immune responses","volume":"323","author":"Chen","year":"2009","journal-title":"Science"},{"key":"2024091013003393700_bib52","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3389\/fimmu.2020.01324","article-title":"Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10","volume":"11","author":"Yin","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2024091013003393700_bib53","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"issue":"10402","key":"2024091013003393700_bib54","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"2024091013003393700_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clml.2017.06.007","article-title":"Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia - a retrospective analysis from the Chronic Malignancies Working Party of the EBMT","volume":"17","author":"van Gelder","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2024091013003393700_bib56","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","article-title":"Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial","volume":"130","author":"Kr\u00e4mer","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2024091013003393700_bib57","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2024091013003393700_bib58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4049\/jimmunol.153.2.666","article-title":"T\u00a0lymphocyte T cell-B cell-activating molecule\/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7\/BB-1) and enhance their costimulatory activity","volume":"153","author":"Yellin","year":"1994","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"2024091013003393700_bib59","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI1472","article-title":"Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells","volume":"101","author":"Kato","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2024091013003393700_bib60","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2024091013003393700_bib61","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-kappaB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ"},{"issue":"3","key":"2024091013003393700_bib62","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood.V92.3.990","article-title":"Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells","volume":"92","author":"Romano","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2024091013003393700_bib63","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/eji.202048761","article-title":"Human CXCR5(+) PD-1(+) CD8\u00a0T cells in healthy individuals and patients with hematologic malignancies","volume":"51","author":"Hofland","year":"2021","journal-title":"Eur J Immunol"},{"issue":"9","key":"2024091013003393700_bib64","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2024091013003393700_bib65","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2024091013003393700_bib66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"6537","key":"2024091013003393700_bib67","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"issue":"499","key":"2024091013003393700_bib68","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024091013003393700_bib69","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T\u00a0cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2024091013003393700_bib70","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2024091013003393700_bib71","doi-asserted-by":"crossref","first-page":"790317","DOI":"10.3389\/fimmu.2021.790317","article-title":"Siglec signaling in the tumor microenvironment","volume":"12","author":"van Houtum","year":"2021","journal-title":"Front Immunol"},{"issue":"8625","key":"2024091013003393700_bib72","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(88)90588-0","article-title":"Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H","volume":"2","author":"Hale","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"2024091013003393700_bib73","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2024091013003393700_bib74","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/jpm12081235","article-title":"CD24: a novel target for cancer immunotherapy","volume":"12","author":"Panagiotou","year":"2022","journal-title":"J\u00a0Personalized Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4633\/2241170\/blooda_adv-2023-011934-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4633\/2241170\/blooda_adv-2023-011934-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T13:01:49Z","timestamp":1725973309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4633\/517132\/T-cell-dysfunction-in-CLL-is-mediated-through"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":74,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011934","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}